| John David Miller, MD | |
|
1615 Hospital Parkway, Suite 306, Bedford, TX 76022 | |
| (817) 684-5106 | |
| (817) 684-5120 |
| Full Name | John David Miller |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 54 Years |
| Location | 1615 Hospital Parkway, Bedford, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831250711 | NPI | - | NPPES |
| 084655201 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | D7189 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Epiphany Dermatology Pa | 3971827791 | 69 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists from Bochum investigate the reorganizational capacity of the adult brain.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Long stigmatized because of its "high"-inducing cousins, hemp - derived from low-hallucinogenic varieties of cannabis - is making a comeback, not just as a source of fiber for textiles, but also as a crop packed with oils that have potential health benefits.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.
› Verified 1 days ago
| Entity Name | John David Miller, M.d.p.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467581439 PECOS PAC ID: 5799750493 Enrollment ID: O20040826001188 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists from Bochum investigate the reorganizational capacity of the adult brain.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Long stigmatized because of its "high"-inducing cousins, hemp - derived from low-hallucinogenic varieties of cannabis - is making a comeback, not just as a source of fiber for textiles, but also as a crop packed with oils that have potential health benefits.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.
› Verified 1 days ago
| Entity Name | Epiphany Dermatology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043615263 PECOS PAC ID: 3971827791 Enrollment ID: O20150126001498 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists from Bochum investigate the reorganizational capacity of the adult brain.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Long stigmatized because of its "high"-inducing cousins, hemp - derived from low-hallucinogenic varieties of cannabis - is making a comeback, not just as a source of fiber for textiles, but also as a crop packed with oils that have potential health benefits.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John David Miller, MD 1615 Hospital Parkway, Suite 306, Bedford, TX 76022 Ph: (817) 684-5106 | John David Miller, MD 1615 Hospital Parkway, Suite 306, Bedford, TX 76022 Ph: (817) 684-5106 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists from Bochum investigate the reorganizational capacity of the adult brain.
Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.
Long stigmatized because of its "high"-inducing cousins, hemp - derived from low-hallucinogenic varieties of cannabis - is making a comeback, not just as a source of fiber for textiles, but also as a crop packed with oils that have potential health benefits.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.
› Verified 1 days ago
Shaun Daniel Cooper, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1600 Central Dr Ste 158, Bedford, TX 76022 Phone: 817-736-2912 Fax: 817-736-2912 | |
George C Baker, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1615 Hospital Parkway, Suite 306, Bedford, TX 76022 Phone: 817-684-5106 Fax: 817-684-5120 | |
Calvin Lamont Williams, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1600 Central Drive, Ste 158, Bedford, TX 76022 Phone: 817-736-2912 Fax: 817-736-2912 | |
Dr. Jorge Roman, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1615 Hospital Pkwy Ste 306, Bedford, TX 76022 Phone: 817-684-5100 | |
Dr. Christopher Kenton Fuller, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1615 Hospital Pkwy Ste 306, Bedford, TX 76022 Phone: 817-684-5100 Fax: 817-684-5101 |